GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » ZYUS Life Sciences Corp (TSXV:ZYUS) » Definitions » Common Stock

ZYUS Life Sciences (TSXV:ZYUS) Common Stock : C$154.09 Mil (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is ZYUS Life Sciences Common Stock?

ZYUS Life Sciences's quarterly common stock increased from Sep. 2023 (C$152.88 Mil) to Dec. 2023 (C$154.09 Mil) but then stayed the same from Dec. 2023 (C$154.09 Mil) to Mar. 2024 (C$154.09 Mil).

ZYUS Life Sciences's annual common stock increased from Dec. 2021 (C$0.00 Mil) to Dec. 2022 (C$92.67 Mil) and increased from Dec. 2022 (C$92.67 Mil) to Dec. 2023 (C$154.09 Mil).


ZYUS Life Sciences Common Stock Historical Data

The historical data trend for ZYUS Life Sciences's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ZYUS Life Sciences Common Stock Chart

ZYUS Life Sciences Annual Data
Trend Dec21 Dec22 Dec23
Common Stock
- 92.67 154.09

ZYUS Life Sciences Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only 92.67 155.70 152.88 154.09 154.09

ZYUS Life Sciences Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


ZYUS Life Sciences (TSXV:ZYUS) Business Description

Traded in Other Exchanges
Address
407 Downey Road, Unit 204, Saskatoon, SK, CAN, S7N 4L8
ZYUS Life Sciences Corp is a next-generation life sciences company engaged in scientific research and development in phyto-therapeutics, including cannabinoid and protein-based formulations. It is committed to delivering high-quality standardized therapeutic formulations that comply with Good Manufacturing Practices (GMP) to provide targeted relief for patients in Canada and globally.
Executives
John Michael Hyshka Senior Officer

ZYUS Life Sciences (TSXV:ZYUS) Headlines

No Headlines